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A b s t r a c t
Background and aim: In patients with mitral stenosis (MS) percutaneous mitral balloon valvuloplasty (PMBV) is used to im-
prove symptoms and prognosis. Although there is some evidence for potential long-term benefits from PMBV in asymptomatic 
patients with mitral valve area (MVA) between 1.0 and 1.5 cm2, there are no follow-up data on patients with symptomatic 
MS with MVA > 1.5 cm2, who underwent PMBV.
Methods: We retrospectively analysed periprocedural results of 113 symptomatic patients who underwent PMBV for MS with 
MVA > 1.5 cm2 (group 1) and compared them with a control group of patients with MVA ≤ 1.5 cm2 (group 2). Clinical and 
procedural variables were compared between groups. 
Results: In group 1, PMBV resulted in a significant increase of MVA as well as a decrease of mean and maximal mitral gradients 
and mean left atrial pressure (LAP), and a subsequent decrease of mean and systolic pulmonary artery pressures (PAPs). Moreover, 
6.3% of patients developed moderate to severe (3+) or severe (4+) post-procedural mitral regurgitation (MR). Post-procedural 
increase in MVA and decrease of LAP were more pronounced in group 2 than group 1 (∆MVA 0.74 cm2 vs. 0.41 cm2, p < 0.05, 
and ∆LAP 8.2 mmHg vs. 6.0 mmHg, p < 0.05). Nonetheless, no significant differences were observed for ∆ of mean and 
systolic PAPs. The grade of post-procedural MR was comparable between groups. 
Conclusions: PMBV is a feasible procedure in highly selected patients without classic echocardiographic indications. None-
theless, it is associated with a small but non-negligible periprocedural risk of developing severe MR.
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INTRODUCTION
In patients with mitral stenosis (MS) interventional treatment 
is used to improve both the symptoms and prognosis. Indica-
tions for interventional treatment in patients with significant 
MS are well-established and proven by extensive evidence.
The current heart valve disease guidelines of the Euro-
pean Society of Cardiology (ESC), the American Heart Asso-
ciation and American College of Cardiology (AHA/ACC) rec-
ommend percutaneous mitral balloon valvuloplasty (PMBV) 
as the first-line therapy in rheumatic patients with isolated 
significant MS and feasible valve morphology. 
The long-term outcome after PMBV is multifactorial [1] 
but mainly determined by the immediate post-procedural 
results. Post-procedural parameters associated with poorer 
late outcome include smaller mitral valve area (MVA), more 
severe mitral regurgitation (MR), higher mean mitral gradient 
(MG), and higher systolic pulmonary artery pressure (PAP) [2]. 
Most common patient-related factors predicting worse out-
come at follow-up included female sex, age, and New York 
Heart Association (NYHA) functional class [3]. Because these 
two types of factors interplay, appropriate pre-interventional 
assessment of valve- and patient-related factors is crucial. 
The treatment strategy is dependent on the stage of MS, 
but no randomised trial has been performed to ascertain 
the best timing of PMBV [2]. This intervention is performed 
increasingly often for indications from both sides, namely in 
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aged patients with more comorbidities and less favourable 
valve morphology and in patients who do not necessarily yet 
meet classic echocardiographic indications. 
A MVA < 2.5 cm2 is usually considered a criterion 
for any MS [4], and the significance of MS is determined 
by MVA < 1.0 cm2, mean MG > 10 mmHg, and systolic 
PAP > 50 mmHg.
In detail, the 2012 ESC guidelines recommend 
PMBV only in symptomatic or asymptomatic patients with 
MVA ≤ 1.5 cm2 [5]. Such a criterion, however, is not based 
on sufficient evidence, but is rather conventionally admit-
ted. Thus, the 2014 AHA/ACC guidelines add a subgroup 
of MS patients who do not meet the above basic criterion 
(MVA ≤ 1.5 cm2) but in whom PMBV may still be considered 
under additional conditions. This subtype of MS is referred to 
as progressive MS, defined as MVA > 1.5 cm2 with evidence of 
haemodynamically significant MS based on pulmonary artery 
wedge pressure > 25 mmHg or mean MG > 15 mmHg dur-
ing exercise (2006 AHA/ACC guidelines mention also systolic 
PAP > 60 mmHg). Such an entity leads to haemodynamic 
consequences expressed by mild to moderate left atrial en-
largement, and these patients may benefit from early PMBV 
(class of recommendation IIb) [6]. 
Interestingly, no criterion of systolic PAP is included in 
the current American indications for PMBV of progressive 
MS, whereas it is already included in European indications 
for PMBV in patients with asymptomatic MS. 
In 1999 Pan et al. [7] addressed the concept of percuta-
neous treatment of mild MS for the first time. All 21 patients 
remained in functional NYHA class II and flexible mitral valve 
was observed in 86% of cases. Mean MVA increased from 
1.7 cm2 to as much as 3.1 cm2 after PMBV, and no significant 
post-procedural MR was observed. Although those results in 
a small study were encouraging, this concept has not gained 
wide acceptance.
Although there is some evidence of potential long-term 
benefits of PMBV in asymptomatic patients with MVA meas-
uring between 1.0 cm2 and 1.5 cm2 [8], there is a lack of fol-
low-up data of symptomatic MS patients with MVA > 1.5 cm2, 
who underwent PMBV. 
In summary, at present there are no data supporting 
more liberal indications for PMBV (level of evidence C in the 
American guidelines) [6].
We retrospectively analysed the immediate periproce-
dural outcomes in patients who underwent PMBV for MS 
with MVA > 1.5 cm2 (group 1) and compared them with 
a propensity score-matched control group of patients treated 
with PMBV for MVA ≤ 1.5 cm2 (group 2).
METHODS
Patient population 
From September 1988 through November 2016, 1794 con-
secutive patients underwent PMBV for rheumatic MS at the 
Institute of Cardiology in Warsaw, Poland. All pre-interven-
tional and interventional data were entered prospectively 
into a database, beginning in 1988. In 85 patients, a repeated 
PMBV was done due to mitral restenosis, and among this 
subgroup seven patients underwent third PMBV for recurrent 
mitral restenosis. The results of this subgroup were published 
previously [9]. Thus, a total of 1886 PMBV procedures were 
performed, of which 116 were done for de novo MS with 
MVA > 1.5 cm2 (group 1). Due to the lack of critical matching 
data (see below), three patients were excluded, and 113 pa-
tients (group 1) were included in further analysis. This group 
was subsequently divided into the following subgroups, ac-
cording to additional echocardiographic and haemodynamic 
parameters: group 1a (mean MG ≤ 10 mmHg) and group 1b 
(mean MG > 10 mmHg). 
The whole cohort of patients with MVA > 1.5 cm2 (group 1) 
was then matched by demographics (sex and age), clini-
cal characteristics (presence of atrial fibrillation [AF]), and 
echocardiographic findings (Wilkins score and MR grade) to 
the equal number of patients with MVA ≤ 1.5 cm2 (group 2) 
by propensity score, and subsequently compared. By anal-
ogy, these patients were divided according to initial systolic 
PAP: group 2a (mean MG ≤ 10 mmHg) and group 2b (mean 
MG > 10 mmHg). 
Indications for PMBV included functional NYHA class II 
or higher, MR ≤ 2+, suitable mitral valve morphology, and 
the absence of concomitant cardiovascular disease requiring 
surgical correction or serious contraindication to necessary 
corrective surgery.
The requirement for informed consent was waived be-
cause of the retrospective nature of this study. 
Echocardiographic evaluation
Each patient underwent transthoracic echocardiographic 
examination on the day preceding PMBV and between 
24 and 48 h after the procedure. The most widely used Wilkins 
scoring was applied to assess the severity of pathological le-
sions in the mitral valve and subvalvular apparatus [10]. MG 
was measured with continuous-wave Doppler, and the MVA 
was determined by planimetry and/or by pressure half-time 
calculation. MR severity was assessed semi-quantitatively or by 
using quantitative methods, and classified as absent (0), mild 
(1+), moderate (2+), moderate to severe (3+), or severe (4+). 
Systolic PAP was measured invasively during periprocedural 
assessment. The size of the left atrium was assessed from the 
leading edge of the anterior wall to the leading edge of the 
posterior wall [11]. Pre-interventional transoesophageal echo-
cardiography was done to exclude the presence of thrombi 
in the left atrium. 
Technique of PMBV
Considering the complexity of PMBV and the learning 
curve [12], the procedure was performed by two of only 
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four experienced cardiologists over the whole study period. 
The technical aspects were described in detail before [5]. 
In short, a transseptal approach was used in all cases under 
local anaesthesia and transoesophageal echocardiographic 
monitoring. Haemodynamic measurements were done during 
the procedure and the Inoue balloon system (Toray Industries 
Inc, Tokyo, Japan) was used to perform the PMBV in all our 
patients. The diameter of the balloon was at the operator’s 
discretion and based on the previously proposed formula [13]. 
Stepwise or single balloon inflation was done at the discretion 
of the operator. 
Definitions of immediate procedural outcome
Success of PMBV was defined as a ≥ 50% increase in baseline 
MVA with an absence of > 2+ increase in the severity of MR.
Failure of PMBV was defined as post-procedural 
MR > 2+. 
Statistical analysis
The statistical evaluation was performed using IBM SPSS 
Statistics 20 (Armonk, NY, USA). Continuous variables were 
presented as mean ± standard deviation and were com-
pared using the Student’s t-test (unpaired and paired) or the 
Mann-Whitney U test, as appropriate. Categorical variables 
were expressed as numbers and percentages and were com-
pared by the c2 test and Fisher’s exact test. 
To reduce the effect of treatment selection bias, analyses 
were performed on the appropriate matched variables. This 
was done on the basis of the propensity score method with 
the nearest neighbour matching on the covariates involving 
sex, age, Wilkins Score, pre-interventional MR grade, and 
the presence of AF. After propensity score matching [14, 15], 
the underlying covariates were compared between matched 
groups with the paired t-test or the Wilcoxon signed-rank test 
for continuous variables, and the c2 test and Fisher’s exact test 
for categorical variables.
Multivariable logistic regression analysis was carried out 
to identify the predictors of procedural success. A p-val-
ue < 0.05 was assumed as a cut-off point to select eligible 
variables for the multiple logistic regression models.
A value of p < 0.05 was considered significant.
RESULTS
The baseline clinical and demographic data of both groups 
are presented in Table 1.
Baseline characteristics
Group 1 consisted of 113 patients (mean age 54.0 ± 10.0 years, 
women; 89.4%). Sinus rhythm was observed in 60.2% of 
patients. Among this group most patients (83.2%) had mean 
MG ≤ 10 mmHg (group 1a).
Procedural characteristics
Comparison of pre- and post-interventional variables within 
group 1 is presented in Table 2. PMBV resulted in improve-
ment of almost all MS-related parameters as expressed 
by increased MVA (from 1.7 ± 0.1 cm2 to 2.0 ± 0.3 cm2, 
p < 0.05), decreased MGs, PAP, and left atrial pressure (LAP), 
respectively. No change in cardiac output was observed. Sig-
nificant post-procedural MR (> 2+) was observed in 6.3% of 
patients; among them, severe MR (4+) was present in 1.8% 
of patients. There was no in-hospital death. 
Control group
Propensity score matching for the whole cohort yielded 
113 matched pairs of patients. A comparison between group 1 
and matched control group 2 is presented in Table 2. 
Patients in group 1 presented with significantly less severe 
heart failure compared to group 2, as expressed by functional 
NYHA class. 
All pre-interventional echocardiographic and invasive 
measurements assessing MS, like MVA (as per definition), 
MGs, LAP, and PAPs, indicated significant differences between 
groups. A trend toward a higher number of patients with systolic 
PAP > 50 mmHg was observed in the control group. Wilkins 
score was similar in both groups. No differences between the 
groups were observed in terms of MR severity or balloon sizes.
By analogy, the same parameters were used to assess 
the mitral valve after PMBV. Although post-interventional 
MS severity expressed by MVA, mean (echocardiographic 
but not haemodynamic) MG, mean PAP, and mean LAP was 
significantly more pronounced in group 2, the rate of PMBV 
success (see definition above) and associated parameters were 
higher in this group. There was no periprocedural mortality. 
The procedural complication rate expressed by MR > 2+ 
was similar in both groups. 
Table 1. Demographic and clinical variables of the study groups
Group 1 Group 2 p
Number of patients 113 113 –
Age [years] 54.0 ± 10.0 53.4 ± 10.2 0.7
Female sex 89.4% 93.8% 0.3
Body mass index [kg/m2] 26.7 ± 4.4 26.7 ± 4.4 0.9
Atrial fibrillation 39.8% 31.8% 0.3
HF NYHA class:
II 80.6% 18.9% < 0.05
III 19.4% 78.4%  < 0.05
IV 0% 2.7% 0.2
Data are shown as mean and standard deviation or percentage.  
HF — heart failure; NYHA — New York Heart Association
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Table 2. Echocardiographic and haemodynamic variables before and after percutaneous mitral balloon valvuloplasty. Intra- and 
inter-group comparison
Before PMBV p After PMBV p  
(intra-group 1)
p  
(inter-groups)Group 1 Group 2 Group 1 Group 2
Number of PMBV procedures 113 113 – – – – –
Wilkins score 6.1 ± 1.4 6.1 ± 1.5 0.9 – – – –
MVA (planimetry)   
cm² 1.7 ± 0.1 1.1 ± 0.2 < 0.05 2.0 ± 0.3 1.8 ± 0.3 < 0.05 < 0.05
∆ – – 0.4 ± 0.3 0.7 ± 0.3 – < 0.05
Mean MG (Doppler)    
mmHg 7.3 ± 3.5 9.4 ± 5.3 < 0.05 4.1 ± 1.5 4.6 ± 2.3 < 0.05 0.06
Group 1a Group 2a
≤ 10 mmHg 83.2% 71.7% 0.05 100% 97.1% < 0.05 0.1
> 10 mmHg Group 1b Group 2b
16.8% 28.3% 0% 2.9%
∆ – – – 3.1 ± 3.4 4.7 ± 5.1 – < 0.05
Maximal MG (Doppler)   
mmHg 14.7 ± 5.5 17.4 ± 6.7 < 0.05 9.2 ± 3.3 10.2 ± 4.0 < 0.05 0.05
∆ – – – 5.3 ± 5.1 7.1 ± 6.0 – < 0.05
MG haemodynamics  4.9 ± 3.2 5.5 ± 3.5 < 0.05 0.2
mmHg 11.3 ± 5.3 14.5 ± 6.1 < 0.05 6.3 ± 3.9 9.0 ± 5.0 – < 0.05
∆ – – –
Systolic PAP   33.6 ± 11.7 38.3 ± 10.3 < 0.05 < 0.05
mmHg 41.9 ± 13.1 48.3 ± 14.6 < 0.05 – –
>50 mmHg 22.6% 33.3% 0.09 8.4 ± 8.0 9.9 ± 9.1 – 0.2
∆ – – –
Mean PAP    
mmHg 27.1 ± 10.2 31.0 ± 10.5 < 0.05 21.8 ± 8.6  25.5 ± 8.5 < 0.05 < 0.05
∆ – – – 5.3 ± 6.9 5.6 ± 6.7 – 0.8
Cardiac output   
L/min 5.1 ± 1.5 4.8 ± 1.3 0.1 5.2 ± 1.4 4.8 ± 1.3 0.4 0.06
∆ – – – 0.0 ± 1.0 0.0 ± 1.0 – 0.7
Mean LAP  
mmHg 20.1 ± 6.7 24.1 ± 7.0 < 0.05 13.9 ± 6.4 15.7 ± 6.2 < 0.05 < 0.05
∆ – – – 6.2 ± 6.5 8.4 ± 6.5 – < 0.05
Size of the left atrium [mm] 47.4 ± 0.7 48.4 ± 0.7 0.3 – – – –
Balloon size [mm] 27.8 ± 1.3 27.9 ± 1.5 0.4 – – – –
Mitral regurgitation:
0 61.1% 69.6% 0.2 45.9% 52.2% < 0.05 0.3
1 31.9% 22.1% 0.1 30.6% 28.3% 1 0.7
2 7.1% 8% 0.8 17.1% 13.3% < 0.05 0.4
3 0% 0% 1 4.5% 4.4% – 1
4 0% 0% 1 1.8% 1.8% – 1
∆MVA ≥ 50% – – – 11.0% 68.9% – < 0.05
Success (∆MVA ≥ 50%  
and no post-MR > 2)
– – – 11.1% 68.9% – < 0.05
Failure (post-MR > 2) – – – 6.3% 6.2% – 1
Data are shown as mean and standard deviation or number or percentage. LAP — left atrial pressure; MG — mitral gradient; MR — mitral  
regurgitation; MVA — mitral valve area; PAP — pulmonary artery pressure; PMBV — percutaneous mitral balloon valvuloplasty
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Prediction of procedural success
Among variables entered in the bivariate analysis, more fre-
quent NYHA class III, lower Wilkins score, smaller pre-inter-
ventional MVA, higher LAP and mean and systolic PAP, and 
higher haemodynamic MG were significantly associated with 
procedural success (see definition above). Apart from Wilkins 
score, all remaining parameters were more frequently associ-
ated with the control group. 
In multivariable logistic regression analysis, lower Wilkins 
score, smaller pre-interventional MVA, and more frequent 
NYHA class III were independent predictors of the procedural 
success (see definition above). 
DISCUSSION
The aim of our study was to focus on symptomatic patients 
with mild MS (MVA > 1.5 cm2), who underwent PMBV. It 
extends the pioneering observations of Pan et al. [7] in a similar 
cohort. Two direct outcome findings are critical.
First, PMBV was effective in this cohort of patients. An 
increase in MVA resulted in a significant decrease of mean 
and maximal MGs as well as PAPs and mean LAP. Although 
the final MVA was larger than in the control group, the rela-
tive increase in MVA was smaller than in the control group. 
Because the balloon sizes were comparable, this only means 
that the dilatation process of stenotic valve was more delicate 
in the studied group than in the control group. 
Second, the rate of post-procedural severe MR in the 
studied group was not negligible, and it was similar in our 
control group as well as in the Korean cohort of patients with 
moderate MS (1.0–1.5 cm2) who underwent PMBV [8]. MR 
was observed despite the fact that post-procedural increase in 
MVA was significantly smaller in our group than in the histori-
cal group of Pan et al [7] (1.7 cm2 to 2.0 cm2 vs. 1.7 cm2 to 
3.1 cm2, respectively). Intuitive interpretation of such results 
is that less aggressive PMBV (as expressed by lower increase 
of post-procedural MVA) does not necessarily protect against 
this complication. 
Impact of MS on left atrial diameter and pressures
Percutaneous mitral balloon valvulopasty does not seem to 
reduce the incidence of AF in patients with significant MS, 
and its influence on the decrease in the incidence of AF in 
patients with mild MS is not clear. This may be explained by 
advanced enlargement of the left atrium secondary to MS, 
which is a well-known and independent predictor of AF in 
MS patients [16]. Patients from both our groups presented 
with at least moderate left atrial enlargement and comparable 
dimensions. This might suggest that even mild MS may lead 
to a change of left atrial geometry, despite lower pre-interven-
tional LAP compared with significant MS. Successful PMBV 
without severe MR immediately decreases LAP and is one 
of the independent predictors of systolic PAP decrease [17]. 
This was also observed in both our groups. Although the LAP 
in group 1 was significantly lower than in the control group, 
PMBV still resulted in significant reduction of LAP in both 
groups. Of note, factors other than MS, such as left ventricular 
diastolic dysfunction, may also contribute to elevated LAP, 
and their presence is associated with a greater risk of failure 
of PMBV to improve symptoms [18].
Impact of PMBV on systolic PAP
Post-capillary pulmonary hypertension is the effect of elevated 
LAP and loss of left atrial compliance. Pulmonary hypertension 
frequently complicates MS, and elevated systolic PAP reflects 
the consequences of MS rather than its severity. Thus, systolic 
PAP is only an additional sign and not a surrogate marker of 
MS severity [19]. Nonetheless, there is a direct correlation 
between successful PMBV and immediate decrease in systolic 
PAP [20], which was also observed in our analysis. The lat-
ter is one of the post-procedural parameters associated with 
long-term outcome [21]. PMBV may even be, to some extent, 
effective in patients with severe pulmonary hypertension 
(systolic PAP > 75 mmHg) [22]. Still, preventive intervention 
before development of pulmonary hypertension is of utmost 
importance because the positive effect of PMBV on right 
ventricular function in the acute period may disappear in 
the mid-term [23].
Correlation between PAP and functional class
We do not have follow-up observations on functional 
class. Still, the scale of PAP has been shown to correlate, at 
least to some extent, with the grade of functional class. It is 
debatable which one of these two factors is more important 
for long-term prognosis.
In patients with idiopathic pulmonary artery hyperten-
sion, the NYHA/World Health Organisation system based on 
the mean right atrial pressure and mean PAP allows separation 
of classes I and II from III and IV [24].
In patients with heart failure and preserved ejection 
fraction, diastolic PAP was one of the parameters that were 
independently associated with advanced NYHA class [25].
Thus, some patients with MS with apparently acceptable 
MVA suffer from effort intolerance. It may be hypothesised 
that this is caused by mild MS. However, such an interpretation 
must be taken with caution. Cohen-Solal et al. [26] found no 
correlation between MVA or MG at rest and maximal upright 
exercise tolerance in patients with MS. This may be explained 
by the fact that other patient-related factors, such as restric-
tive lung function disorders, chronotropic incompetence, 
limited stroke volume reserve, and peripheral factors, are also 
suggested to play a significant role [27]. Nevertheless, these 
factors may be, at least to some extent, a consequence of MS, 
even if not significant according to strict echocardiographic 
criteria. Thus, symptomatic patients even with MVA measur-
ing between 1.6 cm2 and 2.0 cm2 might benefit from PMBV 
[28, 29]. Three explanations were proposed before: 1) the 
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MVA may be smaller than measured due to vagaries of clini-
cal imaging; 2) there is a variable correlation of pulmonary 
vascular resistance with MVA; 3) for a given MVA, MG will 
be higher in persons with a large body surface area (BSA) or 
those with other reasons to have an elevated cardiac output.
Indexing MVA to BSA
Although Singh et al. [30] showed a strong correlation of MVA 
with BSA, no threshold of indexed MVA to BSA has been vali-
dated so far [19]. Thus, indexing to BSA is only recommended 
in the case of aortic valve stenosis or aortic dilatation [5]; 
consequently, we did not perform it.
The lack of data from follow-up observations make it 
impossible to clarify the implication of a very early invasive 
strategy for mild MS. Nonetheless, two aspects are worth 
mentioning. The first one is change in functional class. Results 
from 37 studies indicate that the assessment of functional class 
in mildly symptomatic patients is subjective [31], and patients 
from group 1 in our study remained predominantly in NYHA 
class II. Thus, more reliable measures (like six-minute walk test, 
treadmill or cardiopulmonary exercise testing, or natriuretic 
peptides [32, 33]) would be advisable to prospectively assess 
the change of functional class after PMBV. The other impor-
tant aspect is impact of PMBV on the development of mitral 
restenosis. It may, at least theoretically, lead to MS with more 
pronounced MS-related symptoms, compared with untreated 
mild MS. In our patients with mild MS (group 1), we did not 
observe mitral restenosis after PMBV. Because our matching 
criteria did not exclude patients with mitral restenosis, the 
control group included five patients with mitral restenosis 
after previous PMBV, and eight new patients (7.1%) from this 
group developed mitral restenosis. 
Correlation of pre-interventional PAP and MG
Our results indicate that what makes a greater impact on MGs 
by echocardiography is the pressure (PAP) and not the MVA 
itself (to some extent).
The retrospective design of this single-centre study and 
the lack of randomisation of group 1 to the conservative or 
interventional arm are inherent limitations of this analysis and 
leave room for unmeasured effects on procedural methods 
and outcomes. 
The existence of “progressive MS” is difficult to prove for 
group 1 because the patients were not necessarily assessed 
for increased MG > 15 mmHg during exercise.
Post-procedural complications are only limited to MR. 
Due to the long time span of this retrospective study, we do 
not have reliable data regarding other possible post-procedural 
complications like stroke or access site bleeding.
In conclusion, PMBV may be a relatively safe and feasible 
procedure in highly selected patients who do not meet the 
classic indication for interventional treatment according to 
2012 ECS guidelines. Although it provides good immediate 
results, PMBV is associated with a small, but non-negligible 
periprocedural risk. Thus, indications for PMBV should be 
very carefully assessed and balanced against the inherent 
periprocedural complications. Performance of this procedure 
in patients with larger MVA would require favourable anatomy 
to reduce the incidence of complications. 
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